Skip to content

Organon OGN Acquisitions

Acquisitions at other companies

AbbVie logo
AbbVieABBV
$0-100%
Envista Holdings Corporation logo
Envista Holdings CorporationNVST
$54.4M+1,411%
PBH
Prestige Consumer HealthcarePBH
$30.93M+1,400%
Merck & Co. logo
Merck & Co.MRK
$8.78B
Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
$65M-16.7%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$3.04B+304,000%

Other financials

Income statement

See full
Revenue$1.5B-3.5%
Gross profit$783.0M-6.9%
Net income$146.0M+67.8%
EPS (diluted)$0.55+66.7%

Balance sheet

See full
Cash & equivalents$1.1B+104%
Total debt$8.6B-4.3%
Total equity$903.0M+66.6%
Total assets$13.0B-1.2%

Cash flow

See full
Operating cash flow$225.0M+200%
CapEx$37.0M+15.6%
Free cash flow$188.0M+337%

Valuation

See full
Market cap$3.53B-59.4%

Profitability

See full
Gross margin52.8%-4.4pp
Net margin8%-12.3pp
FCF margin11.1%-1.3pp

Returns & leverage

See full
Return on equity71.6%
Debt / equity9.5×-7.0×
Current ratio+0.3×

Where this comes from

Reported directly by Organon in its filing.

Tagged under the XBRL concept us-gaap:OtherPaymentsToAcquireBusinesses.

The official record: Organon’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Organon's acquisitions.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Organon's acquisitions?
Organon (OGN) reported acquisitions of $0 in Q1 2026.
How has Organon's acquisitions changed year-over-year?
Organon's acquisitions decreased by 100.0% year-over-year, from $75M to $0.
What does acquisitions mean?
Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.